SHILPAMED

Shilpa Medicare Share Price

₹983.55 -2.25 (-0.23%)

17 Jun, 2025 01:30

SIP TrendupStart SIP in SHILPAMED

Start SIP

Performance

  • Low
  • ₹961
  • High
  • ₹1,000
  • 52 Week Low
  • ₹520
  • 52 Week High
  • ₹1,000
  • Open Price₹989
  • Previous Close₹986
  • Volume312,690

Investment Returns

  • Over 1 Month + 37.58%
  • Over 3 Month + 56.48%
  • Over 6 Month + 20.66%
  • Over 1 Year + 84.51%
SIP Lightning

Smart Investing Starts Here Start SIP with Shilpa Medicare for Steady Growth!

Invest Now

Shilpa Medicare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 122.8
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 9,618
  • P/B Ratio
  • 4.1
  • Average True Range
  • 39.08
  • EPS
  • 9.16
  • Dividend Yield
  • 0
  • MACD Signal
  • 63.6
  • RSI
  • 77.85
  • MFI
  • 84.37

Shilpa Medicare Financials

Shilpa Medicare Technicals

EMA & SMA

Current Price
₹983.55
-2.25 (-0.23%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹885.65
  • 50 Day
  • ₹796.58
  • 100 Day
  • ₹758.88
  • 200 Day
  • ₹725.99

Resistance and Support

981.38 Pivot Speed
  • R3 1,041.57
  • R2 1,020.78
  • R1 1,002.17
  • S1 962.77
  • S2 941.98
  • S3 923.37

What's your outlook on Shilpa Medicare?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Shilpa Medicare Ltd. is a leading Indian pharmaceutical company specializing in the development and manufacturing of generic drugs, APIs, and biotechnology products. Focused on oncology and other therapeutic areas, it aims to provide affordable healthcare solutions globally.

Shilpa Medicare Limited has an operating revenue of Rs. 1,286.43 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 10% is healthy, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 32% and 27% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 37 which is a POOR score indicating inconsistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 44 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Shilpa Medicare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-26 Audited Results & Final Dividend
2025-02-10 Quarterly Results
2024-11-13 Quarterly Results
2024-08-08 Quarterly Results
2024-05-23 Audited Results & Final Dividend

Shilpa Medicare F&O

Shilpa Medicare Shareholding Pattern

44.23%
4.05%
2.08%
10.97%
0%
24.42%
14.25%

About Shilpa Medicare

  • NSE Symbol
  • SHILPAMED
  • BSE Symbol
  • 530549
  • Managing Director
  • Mr. Vishnukant C Bhutada
  • ISIN
  • INE790G01031

Similar Stocks to Shilpa Medicare

Shilpa Medicare FAQs

Shilpa Medicare share price is ₹983 As on 17 June, 2025 | 01:16

The Market Cap of Shilpa Medicare is ₹9618.2 Cr As on 17 June, 2025 | 01:16

The P/E ratio of Shilpa Medicare is 122.8 As on 17 June, 2025 | 01:16

The PB ratio of Shilpa Medicare is 4.1 As on 17 June, 2025 | 01:16

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23